COAST Study (Clarifying the Optimal Application of SLT Therapy)
Principal Investigator, Rachel Kuchtey, MD, PhD, and Study Coordinator, Marybeth Carter are collaborating with researchers in the US and UK who have joined with the National Eye Institute to investigate the optimal energy level and frequency of laser therapy to treat glaucoma. Selective laser trabeculoplasty (SLT) has been a treatment option for newly diagnosed open-angle glaucoma or ocular hypertension for nearly 20 years. However, few studies have specifically compared multiple energy levels directly in a head-to-head fashion. We believe that low energy SLT may help people avoid the need to use eye drop medications for a longer time than standard energy SLT.
CLICK HERE to learn more
AGN-193408
Principal Investigator Jeffrey Kammer, MD and Study Coordinator, Alaina Stumpf are participating in a clinical trial with AbbVie to evaluate the efficacy of study treatment AGN-193408 SR (sustained release) to treat open-angle glaucoma or ocular hypertension (high eye pressure). AGN-193408 SR is an experimental implant that is very small and biodegradable (dissolves naturally in the body). AGN-193408 SR contains the study drug prostamide and is placed inside the eye in the intracameral area (between the cornea [the clear part of the eye] and the iris [the colored part of the eye]) or in the posterior chamber (between the iris [the colored part of the eye] and the lens [clear disk behind iris]). Two dose strengths of the study drug AGN-193408 SR will be used in this study, 5 and 7.5 microgram. AGN-193408 SR is expected to release the study drug slowly over 3 to 4 months and the implants will continue to slowly dissolve in about 12 to 24 months. This is the first study to test AGN-193408 SR in humans. If you are interested, please contact Alaina Stumpf at Alaina.stumpf@vumc.org or (615)322-8920.